147 related articles for article (PubMed ID: 12586512)
1. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets.
Takka S; Sakr A; Goldberg A
J Control Release; 2003 Feb; 88(1):147-57. PubMed ID: 12586512
[TBL] [Abstract][Full Text] [Related]
2. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
[TBL] [Abstract][Full Text] [Related]
3. Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.
Ghosh A; Bhaumik UK; Bose A; Mandal U; Gowda V; Chatterjee B; Chakrabarty US; Pal TK
Biol Pharm Bull; 2008 Oct; 31(10):1946-51. PubMed ID: 18827360
[TBL] [Abstract][Full Text] [Related]
4. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of buspirone extended-release tablets: a single-dose study.
Sakr A; Andheria M
J Clin Pharmacol; 2001 Jul; 41(7):783-9. PubMed ID: 11452712
[TBL] [Abstract][Full Text] [Related]
6. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.
Eddington ND; Marroum P; Uppoor R; Hussain A; Augsburger L
Pharm Res; 1998 Mar; 15(3):466-73. PubMed ID: 9563079
[TBL] [Abstract][Full Text] [Related]
7. A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product.
Sakr A; Andheria M
J Clin Pharmacol; 2001 Aug; 41(8):886-94. PubMed ID: 11504277
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation.
Sirisuth N; Augsburger LL; Eddington ND
Biopharm Drug Dispos; 2002 Jan; 23(1):1-8. PubMed ID: 11891668
[TBL] [Abstract][Full Text] [Related]
9. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
10. In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets.
Yaro P; He X; Liu W; Xun M; Ma Y; Li Z; Shi X
Drug Dev Ind Pharm; 2014 Dec; 40(12):1670-6. PubMed ID: 24102615
[TBL] [Abstract][Full Text] [Related]
11. In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug.
Avramoff A; Domb AJ
Int J Clin Pharmacol Ther; 2010 Apr; 48(4):250-8. PubMed ID: 20353746
[TBL] [Abstract][Full Text] [Related]
12. Enhanced bioavailability of buspirone hydrochloride via cup and core buccal tablets: formulation and in vitro/in vivo evaluation.
Kassem MA; Elmeshad AN; Fares AR
Int J Pharm; 2014 Mar; 463(1):68-80. PubMed ID: 24412520
[TBL] [Abstract][Full Text] [Related]
13. In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets.
da Silva JD; de Sousa VP; Cabral LM; Davanço MG; Meulman J; de Oliveira Carvalho P; Campos DR
AAPS PharmSciTech; 2020 Jul; 21(5):195. PubMed ID: 32666354
[TBL] [Abstract][Full Text] [Related]
14. Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate.
Gonçalves de Lima L; Rossi de Campos D
Drug Res (Stuttg); 2016 May; 66(5):225-9. PubMed ID: 26697891
[TBL] [Abstract][Full Text] [Related]
15. Influence of stereoselective pharmacokinetics in the development and predictability of an IVIVC for the enantiomers of metoprolol tartrate.
Sirisuth N; Eddington ND
Pharm Res; 2000 Aug; 17(8):1019-25. PubMed ID: 11028951
[TBL] [Abstract][Full Text] [Related]
16. Development of USP Apparatus 3 Dissolution Method with IVIVC for Extended Release Tablets of Metformin Hydrochloride and Development of a Generic Formulation.
Mendes TC; Simon A; Menezes JCV; Pinto EC; Cabral LM; de Sousa VP
Chem Pharm Bull (Tokyo); 2019; 67(1):23-31. PubMed ID: 30606948
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
18. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
[TBL] [Abstract][Full Text] [Related]
19. Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data.
Mittapalli RK; Marroum P; Qiu Y; Apfelbaum K; Xiong H
Pharm Res; 2017 Jul; 34(7):1527-1533. PubMed ID: 28512718
[TBL] [Abstract][Full Text] [Related]
20. Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride.
Bendas ER
Arch Pharm Res; 2009 Sep; 32(9):1317-29. PubMed ID: 19784589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
